The global Recombinant Human Serum Albumin (HSA) Market is projected to reach USD 116.42 million by 2027, growing at a CAGR of 8.2% from USD 62.11 million in 2019. The market growth is driven by the extensive usage of recombinant DNA technology for drug delivery, drug formulation, cell culture media, vaccine production, and plasma research in laboratory settings. Albumin is a group of acidic...